Please type a plus sign (+) inside this box ->

PTO/SB/08A (08-00) Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO				Complete if Known			
				Application Number	To Be Assigned		
INFORMATION DISCLOSURE				Filing Date	Fcb. 4, 2002 (herewith)	P	
STATEMENT BY APPLICANT			JT.	First Named Inventor	GOLDSMITH	3:	
				Group Art Unit	To Be Assigned		
	(use as many sheets	as necessary)		Examiner Name	To Be Assigned	20	
Sheet	1	of	2	Attorney Docket Number	GLAD001CON	200	

····		I		U.S. PATENT DOCUM	MENTS	
Examin er Initials	Cite No. ¹		cuments Kind Code ² лоwл)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		5,939,320		Littman et al.	08/17/1999	
9		5,529,765		Kindt et al	06/25/1996	
						· · · · · · · · · · · · · · · · · · ·
						747-14-7-1
					·	

		FC	REIGN PATENT DOCUME	NTS		
Examiner Initials'	Cite No. ¹	Foreign Patent Documents	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Office ³ Number ⁴ Kind Code ⁵ (<i>if known</i>)				1
L.		WO/98/18826		05/07/1998		
X		WO/98/58536		12/30/1998		T
						-
						1
						+-
						+-
						+-

Examiner	1		Date	12/12/22
Signature			Considered	14/32/02
		· · · · · · · · · · · · · · · · · · ·		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. Hease type a plus sign (+) inside this box ightarrow

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Inder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

BELLEVE PRAIRE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of

Application Number 10/072,381 RECEIVED
Filling Date February 6, 2002
First Named Inventor Goldsmith, Mark A NUV 0 6 2002
Group Art Unit 1632
Examiner Name To Be Assigned

Examiner Name To Be Assigned
Attorney Docket Number GLAD-001CON TECH CENTER

U.S. PATENT DOCUMENTS								
Examin er Initials'	Cite No. ¹	U.S. Patent Documents Number Kind Code ² (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear			

				FC	REIGN PATENT DOCUME	NTS		
Examiner Initials'	Cite No.1	Foreign Patent Documents			Name of Patentee or	Date of Publication	Pages, Columns, Lines,	
		Office ³	Number ⁴	Kind Code ⁵ (if known)	Applicant of Cited Documents	of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	Т6

		OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
X,	AA	KEPPLER et al., "Progress Toward a Human CD4/CCR5 Transgenic Rat Model for De Novo Infection by Human Immunodeficiency Virus Type 1," <i>J. Exp. Med.</i> , 195(6):719-736 (March 18, 2002)	
	AB	WEI et al., "A Novel CDK9-Associated C-Type Cyclin Interacts Directly with HIV-1 Tat and Mediates Its High-Affinity, Loop-Specific Binding to TAR RNA," Cell, 92:451-462 (February 20, 1998)	
X.	AC	ZHOU et al., "Transcription elongation factor P-TEFb mediates Tat activation of HIV-1 transcription at multiple stages," <i>The EMBO Journal</i> , 17(13):3861-3691 (1998)	

Examiner		Date	12/22/22
Signature	(;	Considered	1722/02

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.